Breathe launches Wearable AI for lung function for COPD, COVID, asthma –


What you should know:

– Today, Respira presents its portable AI technology to control certain very serious lung conditions. According to the Institute for Health Metrics and Assessment, COPD (Chronic Obstructive Pulmonary Disease) and COVID-19 were the third and fourth leading causes of death during the peak of the pandemic. Asthma, according to the World Health Organization, is the most common chronic disease among children.

– The wearable chest uses small speakers and microphones to inject noise into the lungs and “listen” to changes in lung resonance to detect unhealthy lung air entrapment.

Breathe Labs, a medical technology company based in Mountain View, CA that specializes in respiratory care, today announced a new wearable that continuously and easily assesses lung function, without patients exploiting anything. Initially designed to assess patients with COPD, COVID-19, and asthma, the portable patch has built-in speakers and microphones that measure changes in MRI as an indicator of changes in lung air volume, the basis of function tests. pulmonary.

Remote monitoring of patients with COPD, COVID-19 and asthma at home

The chest laptop, named Sylvee, is carried by patients to the bottom of the rib cage. He pays for Medicare and monitors lung function over time to provide an overview of a patient’s condition. Sylvee “injects” noise into the area of ​​the lungs and then measures the type of sound that is produced. Like the beat of a drum, if there is air trapped in the lung, the sound it makes differs from the resonance of the sound produced when air is completely expelled from the lungs. Air entrapment is a central and early symptom of respiratory decline. The Sylvee app uses DSP (digital signal processing) and TO THE analyze the results that pulmonologists and primary care physicians can review, looking specifically at lung volume, capacity, flow rates, and trapped air.

Sylvee Accuracy

Respira Labs has set itself the goal of achieving 90% accuracy in measuring air entrapment by conducting a large trial of more than 500 patients located both in the US and internationally. They also intend to publish it in major journals by the end of 2022. The device is currently in prototype with FDA approval scheduled for the next 18 months.

“Well-established science shows that air entrapment can be measured with more than 90% accuracy using low-frequency sound. There is a clear difference in the acoustic resonance spectrum of patients with COPD versus healthy controls.” explained Dr. Maria Artunduaga, founder and CEO of Respira Lab. “With more than 100 million Americans affected by COPD, COVID-19 and asthma, and an aging population, it can save lives by remotely and accurately controlling lung function and discover a problem well in advance to avoid serious consequences. Our goal is to mark abnormalities early, allow for earlier treatment at home, and train patients to manage their own health. ”

Source link